Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Targeted therapy with imatinib in chronic myeloid leukemia (CML) prompted a new treatment paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant fusion protein kinase but instead displays increased phosphatidylinositol 3-kinase (PI3K) activity. To date, PI3K inhibitor development...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Herman, Sarah E. M., Gordon, Amber L., Wagner, Amy J., Heerema, Nyla A., Zhao, Weiqiang, Flynn, Joseph M., Jones, Jeffrey, Andritsos, Leslie, Puri, Kamal D., Lannutti, Brian J., Giese, Neill A., Zhang, Xiaoli, Wei, Lai, Byrd, John C., Johnson, Amy J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2010
Pynciau:
Lymphoid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2951855/
https://ncbi.nlm.nih.gov/pubmed/20522708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-02-271171
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg